RECIST equivalent for metabolic information leverages the predictive value of PET

In an effort to further promote the utility of PET/CT imaging in assessing the effectiveness of oncology treatments, Siemens Healthcare Molecular Imaging offers a new quantification tool to support PERCIST (PET response criteria in solid tumors). PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria. PERCIST is highlighted this week at the American Society for Therapeutic Radiology and Oncology meeting (Booth # 2715) in San Diego.

Since the introduction of PERCIST, Siemens created a PET/CT quantification tool to aid in the adoption of PERCIST evaluation criteria. Using a consistent PET protocol, and fixed small region of interest, Siemens’ quantification tool evaluates the most active region of metabolically active tumor to minimize statistical variability and offer the most consistent results. Siemens supports industry initiatives with this software tool that will make PERCIST data available and reproducible for every patient so that these criteria will be clinically adopted and used in the field.

“Because Siemens believes in the power of molecular imaging, we have created a PERCIST quantification tool to support the adoption of PERCIST as standard of care,” said Britta Fuenfstueck, CEO, Molecular Imaging, Siemens Healthcare. “An industry-wide adoption of PERCIST criteria for oncology treatment evaluation will further prove the benefit of earlier and more precise detection using the predictive value of PET, and allow physicians to offer more targeted and individualized treatment for patients.”

RECIST is a well established set of rules for determining response to therapy for patients. These criteria were formed on the basis of measuring anatomical changes in tumors using CT imaging. Because PET/CT imaging can detect changes to the tumor at the molecular level, thought leaders in the molecular imaging field introduced PERCIST criteria to use together with RECIST.

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment. PERCIST criteria allow treatment response to be measured in the absence of anatomic change through the assessment of metabolic activity; and often even before anatomical changes take place. The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak SUV within a volume of interest, rather than the common single pixel measure of SUVmax. The PERCIST quantification tool offers a more robust metric that is less susceptible to statistical variation and noise.

 

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2009 (to September 30), the Sector posted revenue of 11.9 billion euros and profit of around 1.5 billion euros. For further information please visit: www.siemens.com/healthcare.